dorsaVi (ASX: $DVL) – Q4 FY25 Highlights
Key Highlights:
- Secured exclusive global licence for advanced RRAM tech from NTU Singapore.
- RRAM integration delivered 50x faster writes and >5,000x faster reads in biomedical sensors.
- Signed 3-year deal with SANO Health and $300k agreement with major Aussie insurer.
- Progressing US expansion with strong clinical and sports project results.
- A $2.44m Capital Raise was undertaken during Q4 with funds secured for RRAM development and to expand dorsaVi’s buisness in the US market.
Link to the announcement: Click Here